Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,800 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Terminated No phase listed Observational

Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

NCT00346372
View directory record Official record
Conditions
Ocular Melanoma
Interventions
Not listed
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 21, 2026, 5:58 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

NCT03278912
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 21, 2026, 5:58 PM EDT
Completed No phase listed Observational

A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD

NCT01437345
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
7
States / cities
Sacramento, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2
Interventions
Technosphere® Insulin Inhalation Powder, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
82
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional

Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00062075
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia
Interventions
romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 21, 2026, 5:58 PM EDT
Recruiting No phase listed Observational

Registry for Systemic Eczema Treatments

NCT06136767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 26 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1

NCT05912400
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Blood draw, FACIT-F and Pain Scales
Diagnostic Test · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

10-Week Physical Activity Program for Mothers of Children With Developmental Disabilities

NCT07182071
View directory record Official record
Conditions
Caregiver Burden
Interventions
Physical Activity Program, Waitlist for Physical Activity Program
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment for Improvement of Cellulite Appearance Using Form Applicator

NCT05882721
View directory record Official record
Conditions
Cellulite
Interventions
Sofwave
Device
Lead sponsor
Sofwave Medical LTD
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
5
States / cities
Sacramento, California • Hackensack, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 3 Interventional

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT03422822
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
3,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
156
States / cities
Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Recruiting Phase 3 Interventional

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
NTLA-2001, Placebo
Biological · Drug
Lead sponsor
Intellia Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
38
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

NCT04135495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX-02, Ivacaftor
Drug
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Long Beach, California • Palo Alto, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients

NCT01075906
View directory record Official record
Conditions
Familial Mediterranean Fever
Interventions
colchicine sprinkle capsules
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
2 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia

NCT02281500
View directory record Official record
Conditions
Congenital Afibrinogenemia
Interventions
Human Plasma-Derived Fibrinogen Concentrate
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
Up to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 21, 2026, 5:58 PM EDT
Active, not recruiting No phase listed Observational

PV Loop & Coarctation Study

NCT05362721
View directory record Official record
Conditions
Coarctation of Aorta
Interventions
Pressure-volume loop catheter
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Terminated Phase 2 Interventional

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

NCT05789537
View directory record Official record
Conditions
Hemophilia B with Inhibitor, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 21, 2026, 5:58 PM EDT
Completed No phase listed Observational

Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank

NCT02706639
View directory record Official record
Conditions
Williams Syndrome, Supravalvular Aortic Stenosis, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Day to 85 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
3
States / cities
Bethesda, Maryland • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Recruiting Not applicable Interventional

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

NCT02744677
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Interventions
SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

28 Day Repeat Dose in Cystic Fibrosis Patients

NCT00903201
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SB656933, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 21, 2026, 5:58 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 1 Interventional

A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery

NCT01034007
View directory record Official record
Conditions
Single Ventricle Cardiac Anomaly
Interventions
Tissue Engineered Vascular Grafts
Combination Product
Lead sponsor
Christopher Breuer
Other
Eligibility
1 Year to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

NCT02312011
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
IONIS-DMPKRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Stanford, California • Gainesville, Florida • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 21, 2026, 5:58 PM EDT
Completed No phase listed Observational

Real World Evidence Study in Subjects With Wilson's Disease

NCT05783687
View directory record Official record
Conditions
Wilson Disease
Interventions
NCC-Sp Assay
Diagnostic Test
Lead sponsor
Orphalan
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2023 – 2025
U.S. locations
9
States / cities
Sacramento, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

NCT06334419
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Gaboxadol, Placebo
Drug
Lead sponsor
Craig Erickson
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 5:58 PM EDT